Outsourcing-Pharma.com presents its weekly round-up of the latest changes, faces and places in the pharma services sector, including news from Wolters, Advanced Clinical and BIA.
Wolters Kluwer has appointed Cathy Wolfe as president of its medical research business.
Wolfe has served as CEO of the online research service provider since 2007, and first joined the business in 1996.
She takes over from Karen Abramson, who leaves to become president and CEO of Wolters Kluwer tax and accounting's CCH business unit.
Wolters Kluwer Health president and CEO Bob Becker will continue to lead the medical research business unit until Wolfe takes over in January.
Of the move, Becker said: "Her (Wolfe’s) global expertise combined with her proven track record of developing and launching innovative products in both electronic and print formats will position our medical research business to continue its focus on delivering leading-edge solutions to meet the evolving needs of our global customers."
Advanced Clinical has named Susan Seroskie its new executive VP of strategic resourcing.
She joins the firm from PharmaNet Development Group where she was global VP of resource solutions.
Leo Sheridan, CEO, said: “Susan’s expertise in the areas of clinical talent, strategic resourcing, and global clinical operations will help us provide increasing levels of value for our clinical research clients. We are honored to bring Susan’s leadership and experience to our team as we expand our contract research organization (CRO) solutions.”
James Yeck has been appointed the new CEO of the European Spallation Source project.
The project – a joint venture between 17 different EU countries – will provide multi-disciplinary analysis based on the world's most powerful neutron source. It is expected to reach completion in 2025.
Yeck takes his place after founding CEO Colin Carlile steps down in March next year. He joins the team from the IceCube neutrino telescope project in the South Pole.
The BioIndustry Association (BIA) has appointed UK MEP (Member of European Parliament) Glenis Willmott as the rapporteur for the European Parliament on the proposed Clinical Trials Regulation.
Steve Bates, BIA’s CEO, said: "Glenis understand the concerns of the UK life science sector and has a strong track record of supporting medical research that can lead to life saving treatments. She understands how the existing rules have played a part in the number of clinical trials in Europe falling over recent years. So, I am delighted that she will be steering this crucial piece of legislation through the European Parliament.”
He went on to cheer the proposed regulation, saying it will save time, money and paperwork for companies wishing to run clinical trials across Europe. “Making Europe a globally attractive place to do clinical trials is essential to sustaining and creating high value life science jobs,” he added.